News
}
Focusing on the 12th International Symposium on DNA-encoded Chemical Libraries: Dr. Bing Xia discussed the strong synergies between differentiated V-DEL and Viva Biotech's multi-technology platforms
Time: 2024-10-23
Source: Viva Biotech
Share:
[Abstract]:Dr. Xia Bing shared several practical examples showcasing the innovative applications of the V-DEL platform.

On October 12, the 12th International Symposium on DNA-encoded Chemical Libraries was held at the Shanghai Tech University Conference Center in China. The symposium brought together the latest advancements in the DEL field from global experts, with discussions on new drug target development, technologies, and case studies from leading pharmaceutical research projects worldwide. Viva Biotech attended the event with a dedicated booth, where Dr. Bing Xia, Vice President and Head of Early Discovery Platforms at Viva Biotech, delivered an insightful presentation titled “Viva's Solution for DEL Platform Setup and Its Application Scenarios.”

 

 

Dr. Xia began by reflecting on his long-standing connection with the symposium, and then introduced Viva Biotech's innovations in DEL solutions. Through rigorous QC processes, Viva Biotech has developed high-quality DEL libraries, which are essential tools in the drug discovery. With hundreds of chemists working across four research centers, Viva Biotech’s large-scale chemistry team and years of experience have enabled the company to design, synthesize, and leverage vast numbers of proprietary building blocks, significantly enhancing the diversity of Viva Biotech’s libraries. Notably, Viva Biotech has expand DNA-compatible reactions (Toolbox), particularly cross-coupling reactions performed at room temperature. This innovative approach addresses the issue of potential DNA damage caused by high temperatures used for this type of key reactions in traditional DEL synthesis. Dr. Xia mentioned that these novel reactions are patent-protected and manuscript is in preparation to detail the advancements. By integrating advanced synthesis methods, abundant chemical resources, and innovative designs, Viva Biotech not only utilizes proprietary, non-commercially available building blocks to enhance the uniqueness and diversity of its libraries, but also continuously optimizes its library design strategies.

 

Case Study: On-DNA Suzuki and Buchwald Coupling at Mild Temperature

 

 

Regarding protein production, Dr. Xia noted that Viva Biotech is capable of studying over 6,000 protein constructs annually, ultimately producing 200-300 different types of proteins, including enzymes, receptors, and membrane proteins. Viva Biotech employs advanced technologies to ensure the quality of proteins used in DEL screening. One standout approach is using Cryo-EM as a high-level QC tool, allowing molecular-level examination of protein structures to ensure correct folding and functional integrity. This innovative method, particularly for GPCR projects, has significantly improved the accuracy and efficiency of screening processes. Viva Biotech operates a comprehensive R&D ecosystem that integrates protein production capabilities with other technologies, such as its affinity screening platform (including SPR and ASMS). These capabilities enable Viva Biotech to rapidly respond to diverse drug discovery needs, from early-stage target investigation, hit identification, all the way to preclinical candidates.

 

Case Study: Cryo-EM Structure Gallery

 

 

Dr. Xia also highlighted Viva Biotech's V-DEL facilitated modality assessment and target triage, designed to optimize resource allocation by prioritizing potential drug targets. Viva Biotech utilizes an "AI powered V-DEL friendly Index" ranking system, which assesses various parameters such as druggability, experimental validation, and target engagement to assign a comprehensive score to each potential target. By leveraging AI technology to analyze vast amounts of data, the platform can quickly identify the most suitable drug modality and assist in preliminary evaluations of multiple potential targets. Dr. Xia shared successful case studies, such as an internal trial where the platform’s index successfully recommended promising cyclic peptides, significantly accelerating the research process and improving success rates. He emphasized that data-driven decision-making reduces subjective biases, providing reliable support for drug discovery, and improving research efficiency.

 

Case Study: AI Powered Cyclic Peptide V-DELs Synthesis

 

 

Finally, Dr. Xia highlighted the synergistic effects of Viva Biotech's one-stop drug discovery platform, which integrates DEL technology with ASMS and SPR. By utilizing AI tools throughout the research process—from proposing building blocks to optimizing lead compounds—Viva Biotech achieves intelligent, end-to-end research workflows.

 

During the exhibition, Viva Biotech showcased a range of cutting-edge technology platforms, including AIDD/CADD, XDC, PROTAC/molecular glue, protein production and structural biology, membrane protein technology, Cryo-EM, Hit screening, Bioassay, DMPK, and therapeutic antibody discovery, demonstrating the company's strong technical expertise in biopharmaceutical R&D. Booth visitors showed great interest in Viva Biotech’s one-stop drug discovery service. Our business development team engaged in-depth discussions with booth visitors, exchanged ideas about Viva Biotech's services and DEL technology. Meanwhile, they explored the possibilities for collaboration on how our integrated services can be combined to enhance efficiency and output. Looking ahead, Viva Biotech eagerly anticipates further collaborating with like-minded partners to advance global biopharmaceutical innovation.

 

Media contact: vivapr@vivabiotech.com
Contact Us